Lycia Therapeutics, Inc. LYCA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.78M | 1.78M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.44M | 10.44M | |||
| Operating Income | -10.44M | -10.44M | |||
| Income Before Tax | -9.60M | -9.60M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.60M | -9.60M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.60M | -9.60M | |||
| EBIT | -10.44M | -10.44M | |||
| EBITDA | -10.22M | -10.22M | |||
| EPS Basic | -0.66 | -0.66 | |||
| Normalized Basic EPS | -0.41 | -0.41 | |||
| EPS Diluted | -0.66 | -0.66 | |||
| Normalized Diluted EPS | -0.41 | -0.41 | |||
| Average Basic Shares Outstanding | 14.49M | 14.49M | |||
| Average Diluted Shares Outstanding | 14.49M | 14.49M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||